Flavio Maina

Centre National de la Recherche Scientifique — France

Medicine · Health Sciences

40h-index5.5kcitations148works0.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Liver physiology and pathology(41), Neurofibromatosis and Schwannoma Cases(21), PI3K/AKT/mTOR signaling in cancer(17), Pluripotent Stem Cells Research(10), Pancreatic function and diabetes(10)

Publications148 total

Abstract PS2-09-12: Splenomegaly and response to chemo-immunotherapy in Triple-Negative Breast Cancer: Findings from MMTV-R26Met mouse model and patients
Clinical Cancer Research·2026
Targeting of a novel interplay between MET tyrosine kinase and NRF2 enhances sensitivity to Paclitaxel in triple negative breast cancer
Journal of Experimental & Clinical Cancer Research·2026Open Access
Multi-omics profiling uncovers immune-molecular clusters with distinct chemo-immunotherapeutic vulnerabilities in a mouse model of triple-negative breast cancer
Molecular Cancer·2026Open Access
Additional file 3 of Targeting of a novel interplay between MET tyrosine kinase and NRF2 enhances sensitivity to Paclitaxel in triple negative breast cancer
Figshare·2026Open Access
Additional file 2 of Targeting of a novel interplay between MET tyrosine kinase and NRF2 enhances sensitivity to Paclitaxel in triple negative breast cancer
Figshare·2026Open Access
Additional file 3 of Targeting of a novel interplay between MET tyrosine kinase and NRF2 enhances sensitivity to Paclitaxel in triple negative breast cancer
Figshare·2026Open Access
Additional file 2 of Targeting of a novel interplay between MET tyrosine kinase and NRF2 enhances sensitivity to Paclitaxel in triple negative breast cancer
Figshare·2026Open Access
Additional file 1 of Targeting of a novel interplay between MET tyrosine kinase and NRF2 enhances sensitivity to Paclitaxel in triple negative breast cancer
Figshare·2026Open Access
Additional file 4 of Targeting of a novel interplay between MET tyrosine kinase and NRF2 enhances sensitivity to Paclitaxel in triple negative breast cancer
Figshare·2026Open Access
Additional file 8 of Targeting of a novel interplay between MET tyrosine kinase and NRF2 enhances sensitivity to Paclitaxel in triple negative breast cancer
Figshare·2026Open Access
Additional file 6 of Targeting of a novel interplay between MET tyrosine kinase and NRF2 enhances sensitivity to Paclitaxel in triple negative breast cancer
Figshare·2026Open Access
Additional file 5 of Targeting of a novel interplay between MET tyrosine kinase and NRF2 enhances sensitivity to Paclitaxel in triple negative breast cancer
Figshare·2026Open Access
Additional file 6 of Targeting of a novel interplay between MET tyrosine kinase and NRF2 enhances sensitivity to Paclitaxel in triple negative breast cancer
Figshare·2026Open Access
Additional file 7 of Targeting of a novel interplay between MET tyrosine kinase and NRF2 enhances sensitivity to Paclitaxel in triple negative breast cancer
Figshare·2026Open Access
Additional file 1 of Targeting of a novel interplay between MET tyrosine kinase and NRF2 enhances sensitivity to Paclitaxel in triple negative breast cancer
Figshare·2026Open Access
Targeting of a novel interplay between MET tyrosine kinase and NRF2 enhances sensitivity to Paclitaxel in triple negative breast cancer
Figshare·2026Open Access
Additional file 7 of Targeting of a novel interplay between MET tyrosine kinase and NRF2 enhances sensitivity to Paclitaxel in triple negative breast cancer
Figshare·2026Open Access
Additional file 4 of Targeting of a novel interplay between MET tyrosine kinase and NRF2 enhances sensitivity to Paclitaxel in triple negative breast cancer
Figshare·2026Open Access
Targeting of a novel interplay between MET tyrosine kinase and NRF2 enhances sensitivity to Paclitaxel in triple negative breast cancer
Figshare·2026Open Access
Additional file 8 of Targeting of a novel interplay between MET tyrosine kinase and NRF2 enhances sensitivity to Paclitaxel in triple negative breast cancer
Figshare·2026Open Access
page 1 of 8Next →

Frequent Co-authors

Rosanna Dono(19), Fabienne Lamballe(10), Carola Ponzetto(8), Paolo M. Comoglio(8), Rüdiger Klein(8), Sylvie Richelme(8), Françoise Helmbacher(7), Alberto Bardelli(6), María Arechederra(5), Fabrice Daian(5), Anice Moumen(5), Alun M. Davies(4), George Panayotou(3), Sehrish Khan Bazai(3), Bianca Habermann(3), Paola Longati(3), Yaron Vinik(3), Gordon B. Mills(3), Sima Lev(3), Annalisa Fico(3)